Safety Information
Wegovy Side Effects Explained
Quick Answer: Wegovy (semaglutide 2.4 mg, and now 7.2 mg for eligible patients) commonly causes nausea, vomiting, diarrhoea, constipation and stomach pain, particularly during the dose escalation phase. At 7.2 mg, gastrointestinal side effects may briefly return or intensify before settling. Most side effects are mild to moderate and ease within four to eight weeks as your body adjusts. Serious side effects are rare but include pancreatitis and gallbladder disease. This page explains every side effect, when to expect it and how to manage it.44%of patients report nausea on Wegovy
4–8 wksfor most GI side effects to ease
2.4–7.2 mgavailable dose range
About Wegovy
What Is Wegovy?
Wegovy is the brand name for semaglutide, a once-weekly injectable treatment approved in the UK for chronic weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related health condition. It is available at doses up to 2.4 mg (standard maintenance) and 7.2 mg (higher-dose option for eligible patients). It is manufactured by Novo Nordisk and is dispensed in the UK only through GPhC-registered pharmacies.
Semaglutide belongs to a class of medicines called glucagon-like peptide-1 (GLP-1) receptor agonists. GLP-1 is a naturally occurring hormone released from the gut after eating. By mimicking GLP-1 at a pharmacological dose, Wegovy reduces appetite, slows gastric emptying and influences reward pathways in the brain associated with food cravings.
How Is It Administered?
Wegovy is self-administered as a subcutaneous injection once per week using a pre-filled, single-use pen. Common injection sites include the abdomen, thigh or upper arm. Patients begin on a low starting dose of 0.25 mg and escalate over approximately 16 to 20 weeks to the standard maintenance dose of 2.4 mg. Eligible patients may then escalate further to 7.2 mg, which is delivered using a different single-dose device rather than the standard pen.
Is Wegovy Approved in the UK?
Yes. Wegovy received MHRA approval in September 2021 and NICE recommended it for use within specific eligibility criteria in March 2023 (TA875). It is available through both the NHS (via specialist weight management services) and through regulated private pharmacies such as Happy Pharmacy (GPhC No. 9012585).
Mechanism
Why Does Wegovy Cause Side Effects?
Understanding why Wegovy causes side effects helps patients approach them with realistic expectations rather than alarm. The majority of side effects are a direct consequence of the drug's mechanism of action rather than a sign that something is wrong.
The GLP-1 Mechanism and the Gut
GLP-1 receptors are distributed throughout the gastrointestinal tract. When semaglutide activates these receptors, it slows the rate at which food moves from the stomach into the small intestine — a process known as gastric emptying. This is beneficial for weight loss because it prolongs feelings of fullness, but it also means food sits in the stomach for longer than usual, which commonly produces nausea, bloating and discomfort, particularly after larger meals.
Central Nervous System Effects
GLP-1 receptors are also present in areas of the brain involved in appetite regulation and nausea signalling, including the area postrema — sometimes called the body's vomiting centre. Stimulation of these receptors contributes to appetite suppression but can also trigger nausea and, less commonly, vomiting. This neurological component explains why some patients experience nausea even when they have eaten very little.
Why Side Effects Are Dose-Dependent
The structured dose escalation schedule — starting at 0.25 mg before gradually increasing to 2.4 mg — exists specifically to reduce the severity and frequency of side effects. Each dose increase temporarily increases the likelihood of gastrointestinal symptoms as the body recalibrates. Clinical trials demonstrate that side effects peak during dose escalation and diminish significantly once patients stabilise on their maintenance dose. This same pattern applies when escalating from 2.4 mg to 7.2 mg — a temporary increase in gastrointestinal symptoms is expected before the body adapts.
Common Side Effects
Common Wegovy Side Effects
The following side effects are defined as common (occurring in 1 in 10 or more patients) based on data from the STEP clinical trial programme, which involved over 4,500 participants across multiple studies.
Nausea
Nausea is the most frequently reported Wegovy side effect and affects approximately 44% of patients in clinical trials. It is most pronounced during the first four weeks of treatment and at each dose escalation point. The mechanism is twofold: slowed gastric emptying causes a sensation of fullness and discomfort, while GLP-1 receptor stimulation in the brain's nausea centres adds a neurological component. Most patients describe Wegovy nausea as manageable rather than severe, and it typically resolves without requiring dose reduction.
Gastrointestinal Side Effects
Diarrhoea, vomiting, constipation and abdominal pain frequently occur together as part of a broader pattern of gastrointestinal adjustment. Diarrhoea tends to emerge in the early weeks as the gut adapts to altered transit times. Constipation often follows as gastric emptying slows further on higher doses. Patients should remain well hydrated throughout treatment, as both diarrhoea and reduced appetite can contribute to dehydration.
Headache and Fatigue
Headache and fatigue in the early weeks of Wegovy treatment are often related to reduced calorie intake and altered eating patterns rather than a direct pharmacological effect. As appetite decreases substantially, some patients inadvertently under-fuel their activity levels. Ensuring adequate protein intake and staying hydrated can reduce the frequency and severity of these symptoms.
| Side Effect | Frequency (STEP Trials) | Typical Onset |
|---|---|---|
| Nausea | 44% | Weeks 1–4 |
| Diarrhoea | 30% | Weeks 1–6 |
| Vomiting | 24% | Weeks 1–4 |
| Constipation | 24% | Weeks 2–8 |
| Abdominal pain | 20% | Weeks 1–8 |
| Headache | 14% | Weeks 1–3 |
| Fatigue | 11% | Weeks 1–6 |
| Indigestion | 9% | Variable |
| Dizziness | 7% | Variable |
| Belching / bloating | 7% | Weeks 1–8 |
Dose Timeline
Week-by-Week Side Effects Timeline
The following timeline is based on data from the STEP 1 trial and clinical observations from weight management practice. Individual experiences will vary.
| Period | What to Expect |
|---|---|
| Weeks 1–4 (0.25 mg) | Nausea is most common in these early weeks, typically peaking around injection day and easing over 48 hours. Mild stomach discomfort and occasional loose stools are normal. Most patients find symptoms manageable by adjusting meal size and timing. |
| Weeks 5–8 (0.5 mg) | Dose escalates to 0.5 mg. Nausea may temporarily increase. Constipation becomes more common as gastric emptying slows further. Headache and fatigue may persist but typically begin to ease. |
| Weeks 9–12 (1.0 mg) | Further escalation to 1.0 mg. Appetite suppression becomes more pronounced. GI symptoms often begin to settle into a predictable pattern. Many patients report that symptoms feel more manageable at this stage. |
| Weeks 13–16 (1.7 mg) | Penultimate dose step. Nausea may briefly return. The window of greatest weight loss acceleration often begins here as appetite is substantially reduced. |
| Week 17+ (2.4 mg) | Full maintenance dose reached. Side effects for most patients are significantly reduced compared to the early weeks. Nausea becomes infrequent. Energy levels often stabilise as eating patterns normalise around a lower calorie intake. |
| Week 21+ (7.2 mg) | Optional higher dose for eligible patients. GI side effects (nausea, diarrhoea) may temporarily return, mirroring earlier escalation steps. Symptoms typically ease within 2–3 weeks. Some patients notice unusual skin sensations such as tingling, numbness or a crawling feeling — more common at this dose. If GI symptoms are severe, returning to 2.4 mg is clinically appropriate. |
Patient Note: The escalation schedule is designed to minimise discomfort. If side effects at any stage are intolerable, speak to your prescribing pharmacist or clinician before adjusting your dose. Happy Pharmacy's clinical team is available throughout your treatment.
By Dose
Which Dose Causes the Most Side Effects?
Clinical data from the STEP trials consistently demonstrates that side effects are most frequent and most intense during dose escalation rather than at the steady maintenance dose of 2.4 mg. Each dose increase temporarily raises the likelihood of nausea, vomiting and gastrointestinal discomfort as the body adapts to higher semaglutide concentrations.
The 1.0 mg and 1.7 mg Steps
The escalation steps from 1.0 mg to 1.7 mg represent the period when many patients notice the most significant appetite suppression alongside the highest incidence of nausea. At these doses, semaglutide's effect on gastric emptying and central appetite centres is substantially more pronounced than at the starting dose. Patients who have managed the lower doses well should be reassured that symptoms at these steps are typically transient.
Maintenance at 2.4 mg
Counterintuitively, many patients find that symptom burden actually decreases once they reach the 2.4 mg maintenance dose. The body has had 16 to 20 weeks to adapt to the drug's mechanism of action, and the absence of any further dose change allows symptoms to stabilise. Nausea, in particular, tends to become rare at maintenance for patients who have completed the full escalation schedule.
| Dose | Reported Nausea (approx.) |
|---|---|
| 0.25 mg | ~30% of patients, typically mild |
| 0.5 mg | ~38% of patients, mild to moderate |
| 1.0 mg | ~44% of patients, peak nausea period |
| 1.7 mg | ~41% of patients, beginning to ease |
| 2.4 mg | ~20–25% of patients, mostly mild |
| 7.2 mg | ~25–30% transiently on escalation, then easing; some patients report tingling or unusual skin sensations at this dose |
Managing Side Effects
Managing Nausea on Wegovy
Wegovy nausea is real, but it is manageable for the vast majority of patients. The following evidence-informed strategies can significantly reduce its severity and duration.
Dietary Adjustments
The most effective single intervention for managing Wegovy nausea is eating smaller meals more frequently. Large meals distend the stomach and compound the discomfort caused by slowed gastric emptying. Patients should aim for three to four small meals per day rather than one or two larger ones. Foods that are high in fat, spicy, very sweet or heavily processed are more likely to trigger nausea and are best minimised during the early weeks of treatment.
- Eat slowly and chew food thoroughly
- Stop eating before you feel full — semaglutide reduces the fullness signal, making it easy to overeat initially
- Choose bland, easily digestible foods during nausea flare-ups: plain rice, toast, boiled chicken, bananas
- Avoid lying down immediately after eating
- Cold or room-temperature foods may be better tolerated than hot dishes
| Side Effect | Notes |
|---|---|
| Injection site reactions | Redness, bruising or mild swelling at the injection site. Rotating injection sites reduces frequency. |
| Hair thinning (telogen effluvium) | Temporary hair shedding linked to rapid weight loss and calorie restriction rather than semaglutide directly. Usually resolves within 6 months. |
| Low blood sugar (hypoglycaemia) | Rare in patients not also taking insulin or sulphonylureas. More common in type 2 diabetes patients on combination therapy. |
| Increased heart rate | A small increase in resting heart rate (approximately 2–4 bpm) has been observed in trials. Not clinically significant for most patients. |
| Acid reflux / GERD | Slowed gastric emptying can worsen reflux symptoms. Eating smaller meals and avoiding lying flat after eating helps. |
| Sleep disturbance | Reported by a minority of patients, particularly in the first few weeks. Often linked to gastrointestinal discomfort overnight. |
| Mood changes | A small number of patients report improved mood as weight loss progresses. Rare reports of low mood or anxiety exist — speak to your clinician if concerned. |
Safety
Serious Wegovy Side Effects
Important: This section is for awareness only and does not replace professional medical advice.
If you experience any of the following symptoms, seek medical attention promptly. Always contact 111, your GP or A&E if you are concerned about any symptom during Wegovy treatment.
Pancreatitis
Pancreatitis (inflammation of the pancreas) has been reported in patients taking GLP-1 receptor agonists including semaglutide, though causality has not been definitively established. The incidence in STEP trials was low (under 0.3%). Warning signs include severe, persistent abdominal pain that radiates to the back, which may be accompanied by vomiting. Treatment should be discontinued and medical advice sought immediately if these symptoms occur.
Gallbladder Disease
Cholelithiasis (gallstones) occurred in approximately 1.6% of Wegovy patients in the STEP 1 trial compared with 0.7% in the placebo group. Rapid weight loss itself increases gallstone risk, which may partly explain this finding. Symptoms of gallbladder disease include sharp pain in the upper right abdomen, particularly after eating fatty foods, and should be investigated by a clinician.
Thyroid Effects (Precautionary Warning)
In rodent studies, semaglutide was associated with thyroid C-cell tumours. This finding has not been replicated in human studies and is considered a precautionary observation. However, Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Patients should not start Wegovy without disclosing full medical history to their prescribing clinician.
Diabetic Retinopathy
A slightly higher rate of diabetic retinopathy complications was observed in the SUSTAIN 6 trial among patients with type 2 diabetes. This was not observed in the STEP trials. Patients with a history of diabetic eye disease should discuss this with their prescribing clinician before starting Wegovy.
Severe Allergic Reactions
Serious allergic reactions (anaphylaxis or angioedema) to semaglutide are rare but have been reported. Symptoms include swelling of the face, lips, tongue or throat, difficulty breathing, rapid heartbeat or collapse. If any of these occur after injection, seek emergency medical help immediately and do not take further doses.
When to Seek Medical Advice
| Symptom | Action |
|---|---|
| Persistent nausea despite dietary adjustments | Contact your prescribing pharmacist or clinician for advice |
| Vomiting that prevents keeping food or fluids down | Contact your prescribing clinician — dose review may be needed |
| Severe abdominal pain radiating to the back | Seek urgent medical attention — possible pancreatitis |
| Upper right abdominal pain after eating | Contact your GP — possible gallbladder issue |
| Signs of dehydration (dizziness, dark urine, dry mouth) | Seek medical attention and increase fluid intake |
| Swelling of face, lips or throat | Call 999 immediately — possible severe allergic reaction |
| Rapid or irregular heartbeat | Seek medical advice promptly |
| Low blood sugar (shakiness, confusion, sweating) | Check blood glucose if diabetic; contact clinician if recurring |
| Significant mood change or depression | Contact your GP or mental health professional |
| Lump or swelling in the neck | Contact your GP — should be assessed for thyroid abnormality |
Happy Pharmacy Clinical Support: All Happy Pharmacy patients have access to clinical support throughout their treatment. Our GPhC-registered pharmacists are available to advise on side effect management, dose adjustments and when to seek further medical review. Contact us through HappyPharmacy.co.uk.
Key Questions
Key Questions Answered
What are the most common Wegovy side effects?
The most common Wegovy side effects are nausea (affecting approximately 44% of patients), diarrhoea (30%), vomiting (24%), constipation (24%) and abdominal pain (20%). These are all gastrointestinal in nature and arise because semaglutide slows stomach emptying and activates GLP-1 receptors throughout the gut. Headache and fatigue are also common, particularly in the first few weeks of treatment. The majority of these side effects are mild to moderate in severity and ease significantly as the dose escalates and the body adapts.
How long do Wegovy side effects last?
For most patients, Wegovy side effects are most pronounced during the first four to eight weeks of treatment and at each dose escalation step. By the time patients reach the maintenance dose of 2.4 mg — typically around week 17 to 20 — side effects have usually reduced substantially. Patients who then escalate to 7.2 mg should expect a brief recurrence of gastrointestinal symptoms, which typically settles within two to three weeks. Nausea, the most common complaint, tends to occur on and around injection day in the early weeks but becomes less frequent and less intense over time. A minority of patients experience persistent mild nausea throughout treatment, but this rarely requires discontinuation.
Does nausea go away on Wegovy?
Yes, for the vast majority of patients. Nausea on Wegovy is most common during the dose escalation phase and typically improves once the body adapts to each new dose level. By the maintenance phase at 2.4 mg, most patients report that nausea has resolved or occurs only occasionally. Dietary strategies — including eating smaller meals, avoiding fatty or spicy foods, and staying well hydrated — can significantly reduce nausea during the adjustment period. Patients who continue to experience troublesome nausea should speak to their prescribing clinician, as a slower escalation schedule may help.
FAQs
Frequently Asked Questions: Wegovy Side Effects
Nausea is the most commonly reported Wegovy side effect, affecting around 44% of patients during clinical trials. It is most pronounced in the early weeks of treatment and at each dose escalation step. The majority of patients describe it as manageable rather than severe, and it typically eases significantly within four to eight weeks.
Nausea tends to peak around the 1.0 mg and 1.7 mg dose steps for most patients. Counterintuitively, many patients find that nausea actually decreases once they reach the 2.4 mg maintenance dose. Patients who escalate further to 7.2 mg may experience a temporary return of nausea at that step, but it typically settles within two to three weeks.
Over-the-counter antiemetics such as cyclizine are sometimes used for short-term nausea relief during Wegovy treatment. However, you should speak to your prescribing pharmacist or doctor before taking any additional medication, as interactions and suitability vary depending on your full medical history.
Clinical trials have followed patients for up to 72 weeks (STEP UP), and ongoing real-world evidence is accumulating. Wegovy has a well-characterised safety profile and has been approved by both the MHRA and NICE. Serious adverse events are rare. Patients should attend regular monitoring appointments as recommended by their prescribing clinician.
Constipation on Wegovy is a direct consequence of slowed gastric emptying — semaglutide reduces the speed at which food moves through the digestive system. Staying well hydrated, eating adequate dietary fibre, and maintaining light physical activity can all help manage constipation. If it becomes troublesome, speak to your pharmacist.
A small proportion of patients notice temporary hair thinning during Wegovy treatment. This is most commonly attributed to rapid weight loss and calorie restriction rather than to semaglutide itself — a condition known as telogen effluvium. Hair growth typically returns within six months without any specific treatment.
Yes, abdominal pain is a common Wegovy side effect, reported by approximately 20% of patients in clinical trials. It is usually mild to moderate and related to the slowing of gastric motility. Severe or persistent abdominal pain — particularly if it radiates to the back — should be assessed urgently as it can rarely indicate pancreatitis.
Smaller, more frequent meals are the most effective dietary strategy for reducing Wegovy side effects. Bland, easily digestible foods such as plain rice, toast, bananas and boiled chicken are better tolerated. Fatty, spicy, heavily processed or very sweet foods tend to worsen nausea and should be limited during the early weeks of treatment.
The majority of patients who experience side effects do not need to discontinue treatment. In the STEP 1 trial, around 7% of participants discontinued due to gastrointestinal side effects — compared with under 4% in the placebo group. A slower escalation schedule or temporary dose pause can help patients who find side effects difficult to manage.
A small number of patients have reported mood changes during GLP-1 receptor agonist treatment. Some experience improved mood associated with weight loss; a rare minority report feelings of low mood or anxiety. Patients with a history of depression or other mental health conditions should discuss this with their prescribing clinician before starting Wegovy. Ongoing monitoring is recommended.
If you miss your weekly dose by five days or fewer, take it as soon as you remember. If more than five days have passed, skip the missed dose and take the next one on your usual scheduled day. Do not take two doses in one week. A single missed dose is unlikely to cause significant side effects on resumption.
Patients escalating to 7.2 mg should expect a temporary return of GI side effects — nausea and diarrhoea in particular — mirroring the pattern seen at earlier dose steps. These typically settle within two to three weeks. Some patients also report unusual skin sensations such as tingling, numbness or a crawling feeling, which are more common at the 7.2 mg dose. If symptoms are severe, returning to 2.4 mg is clinically appropriate.
Ready to Start Wegovy Treatment?
GPhC-registered pharmacy (No. 9012585) · UK-licensed prescribers · Free online assessment · Superintendent Pharmacist: Palvinder Deol · Trustpilot 4.8 ★
Check Your Eligibility →
Wilding JPH et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002. | Semaglutide 2.4 mg for the Treatment of Obesity (STEP 3). JAMA. 2020;323(12):1188–1195. | Wharton S et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP). Lancet Diabetes Endocrinol. 2025;S2213–8587(25):00226–8. | MHRA. Semaglutide (Wegovy) prescribing information. 2023. gov.uk/mhra | NICE TA875. Semaglutide for managing overweight and obesity. 2023. | Novo Nordisk. Wegovy (semaglutide 2.4 mg and 7.2 mg) Summary of Product Characteristics. 2023/2025. | GPhC. Standards for registered pharmacies. 2023. gphc.org.uk | Happy Pharmacy (GPhC No. 9012585). Educational purposes only — not a substitute for individualised clinical assessment.